Process for preparation of 4-[5-[bis (2-chloroethyl) amino]-1-methyl-1h-benzo [d] imidazol-2-yl] butyric acid alkyl esters and formylated derivatives

The use of chloromethylenedimethyliminium chloride in the preparation of alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate addresses the impurity and safety issues of existing methods, achieving high yields and enabling the production of a formylated derivative with antitumor potential.

CN119095829APending Publication Date: 2024-12-06HERAEUS PRECIOUS METALS GMBH & CO KG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033611.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-04
Filing Date
2023-01-16
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing process for preparing alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate results in undesirable yellow coloration due to unknown impurities, which are difficult to remove, and involves the use of hazardous substances like oxalyl chloride and dimethylformamide, making it challenging to control the reaction.

Method used

A process using chloromethylenedimethyliminium chloride in a stoichiometric or superstoichiometric ratios to convert alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate, allowing for better control of the reaction and minimizing impurities, with the option to form novel 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate as a by-product.

Benefits of technology

The new process achieves high yields of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate with fewer impurities, avoids hazardous substances, and allows for the production of a novel formylated derivative with potential antitumor effects, suitable for further derivatization reactions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A process for the preparation of 4-[5-[bis (2-chloroethyl) amino]-1-methyl-1H-benzo [d] imidazol-2-yl] butyric acid alkyl ester wherein 1 mol of 4-[5-[bis (2-hydroxyethyl) amino]-1-methyl-1H-benzo [d] imidazol-2-yl] butyric acid alkyl ester is reacted with 2.0 mol to 2.2 mol of chloromethylenedimethyl imine chloride or with gt; the present invention relates to a process for the preparation of alkyl 4-[5-[bis (2-chloroethyl) amino]-4-formyl-1-methyl-1H-benzo [d] imidazol-2-yl] butyrate by reacting 4-[5-[bis (2-chloroethyl) amino]-4-formyl-1-methyl-1H-benzo [d] imidazol-2-yl] butyrate with 2 mol to 5 mol of chloromethylenedimethyl imine chloride to produce a byproduct in the form of alkyl 4-[5-[bis The alkyl ester can be hydrolyzed to form 4-[5-[bis (2-chloroethyl) amino]-4-formyl-1-methyl-1H-benzo [d] imidazol-2-yl] butyric acid, which is useful in the medical field.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a method for preparing 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester and its formylated derivatives.

[0002] Ester hydrolysis can result in the conversion of alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate to 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid. 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid is known as an antitumor agent named "Bendamustine".

[0003] EP 2 468 716 A1 discloses a process for preparing alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate. The reactant used is alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate, the hydroxyethyl group of which can be converted into a chloroethyl group by reaction with oxalyl chloride in the presence of dimethylformamide to form alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate. Although it is possible to work stoichiometrically, i.e. in a molar ratio of 2.0 mol oxalyl chloride: 1 mol alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate, EP 2 468 716 A1 recommends preferably using a stoichiometric excess corresponding to a molar ratio of ≥ 2.6 mol, in particular at least 3.0 mol, of oxalyl chloride per mole of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate. The in situ reaction of oxalyl chloride with dimethylformamide used here is difficult to control with regard to the integrity of the reaction or unwanted interfering moisture in the reaction system. If the teaching of EP 2 468 716 A1 is followed and the superstoichiometric molar ratio recommended as preferred is used, the desired 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester in question is obtained in good yield, but with an undesirable yellow coloration, which is caused by hitherto unknown impurities and is difficult to remove even when treated with activated carbon. The intensity of the yellow coloration increases with the selected molar ratio of oxalyl chloride to 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester.

[0004] The object of the present invention is to provide an improved process for the preparation of alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate starting from alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate.

[0005] This object can be achieved by a process for preparing alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate by reacting alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate with chloromethylenedimethylimine chloride having the formula ClCH=N(CH3)2Cl.

[0006] In a first embodiment, the preparation process according to the present invention can be carried out with a practical stoichiometric molar ratio of chloromethylenedimethylimine chloride in the range of 2.0 mol to 2.2 mol per mole of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid alkyl ester, with a good yield of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid alkyl ester and with few impurities and few by-products.

[0007] However, in a second embodiment, the preparation process according to the invention can also be carried out with a superstoichiometric molar ratio of chloromethylenedimethylimine chloride in the range of >2.2 mol to, for example, 5 mol per mole of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate. However, the choice of a superstoichiometric molar ratio is less preferred in view of obtaining a high yield of alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate.

[0008] Preferably, the alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate reacted with chloromethylenedimethyliminium chloride in the process according to the invention is C 1-4 an alkyl ester, in particular ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate; in other words, a preferred embodiment of the process according to the invention consists in using chloromethylenedimethyliminium chloride and 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid C 1-4The method is carried out by using an alkyl ester, in particular ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate. Thus, 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate C is obtained. 1-4 Alkyl esters, in particular ethyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate, are products of a preferred embodiment of the process according to the invention.

[0009] Chloromethylenedimethyliminium chloride is commercially available from, for example, Sigma-Aldrich. It is a solid.

[0010] The synthesis method according to the present invention can advantageously be used in E T (30) values ​​range from 140 kJ / mol to 193 kJ / mol in aprotic, anhydrous (dry) organic solvents or in mixtures of such solvents. Examples of such solvents include chlorinated organic solvents such as dichloromethane and chloroform, ethers such as dioxane and tetrahydrofuran, and acetonitrile.

[0011] The two reactants used in the synthesis method according to the invention (chloromethylenedimethyliminium chloride and 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester) can react with each other in solution or in suspension, wherein in the latter case, one or both reactants can be present as a suspension. The two reactants can be added in any order, dissolved, suspended or added as a solid.

[0012] In the process according to the invention, it is possible to work with a ratio of reactant amounts (total amount of both reactants) in the range of, for example, 30 g to 150 g per liter of organic solvent (mixture).

[0013] It is useful to maintain the temperature of the reaction mixture during the addition of the reactants and during the reaction, for example, in the range of 0°C to 60°C.

[0014] For example, the reaction time may be in the range of 30 minutes to 360 minutes.The reaction mixture is preferably mixed, in particular stirred.

[0015] After the reaction is completed, water may be added, and the pH value may be adjusted by adding a base, for example, within the range of 7 to 10. Examples of the base that may be used include ammonia, alkali metal hydroxides, alkali metal carbonates, and alkali metal hydrogen carbonates.

[0016] If the reaction is carried out in a water-immiscible solvent, the alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate formed in the process according to the invention is in the organic phase after addition of water and pH adjustment. In addition, the alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate formed can be converted into a water-immiscible organic phase after addition of a water-immiscible solvent such as dichloromethane and recovered and purified therefrom by conventional methods familiar to organic chemists. Examples of such methods include crystallization, precipitation using an antisolvent and preparative chromatography.

[0017] The alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoates prepared according to the process of the invention can be subjected to ester hydrolysis to form 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid or its hydrochloride, for example in analogy to the procedure known from EP 2 468 716 A1.

[0018] Compared with the production process known from EP 2 468 716 A1, the production process according to the invention has many advantages:

[0019] 1. From the point of view of occupational safety, the use of chloromethylenedimethyliminium chloride instead of oxalyl chloride / dimethylformamide as the chlorinating agent is preferred in several respects. In addition to the advantage of avoiding the handling of hazardous substances oxalyl chloride and dimethylformamide, the exothermic reaction and gas formation associated with the reaction of oxalyl chloride with dimethylformamide can also be avoided.

[0020] 2. The use of chloromethylenedimethyliminium chloride allows accurate dosing with respect to the adjustment of the desired stoichiometric or superstoichiometric molar ratio between chloromethylenedimethyliminium chloride and 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester; it also allows subsequent dosing of chloromethylenedimethyliminium chloride, if necessary.

[0021] 3. Avoidability or reducibility of side reactions, in particular when the process according to the invention is carried out with a practically stoichiometric molar ratio of chloromethylenedimethylimine chloride in the range of 2.0 mol to, for example, 2.2 mol per mole of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate.

[0022] 4. Lower base consumption when adjusting pH after reaction completion.

[0023] As mentioned above, the preparation process according to the invention in its second embodiment can also be carried out with a superstoichiometric molar ratio of chloromethylenedimethylimine chloride in the range of >2.2 mol to, for example, 5 mol per mole of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester. 1-4 When the process according to the invention is carried out with alkyl esters, in particular ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate in a molar ratio of chloromethylenedimethylimine chloride in the range of 2.6 mol to 5 mol, a yellow coloration similar to the yellow coloration already mentioned at the beginning can be observed in the reaction system, which increases with increasing stoichiometric excess of chloromethylenedimethylimine chloride. The substance causing the yellow coloration is a process by-product of the process according to the invention in its second embodiment and has now been identified or isolated for the first time as previously unknown and therefore derived from 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid C 1-4 The invention relates to novel compounds of the group of alkyl esters. It is clear that when the process according to the invention is carried out in its second embodiment, a regioselective formylation of the actual main process product at the 4-position of its benzo[d]imidazole backbone can occur. After separation from the main process product 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]-butyric acid ethyl ester, the corresponding previously unknown and therefore novel 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid ethyl ester is obtained and characterized. Thus, 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid ethyl ester is a process by-product formed when the process according to the invention is carried out in its second embodiment. Due to its structural relationship with 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid, ethyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate can also be expected to have antitumor effects. Its aldehyde group as a reactive functional group can provide a starting point for a variety of intramolecular and intermolecular derivatization reactions and thus provide a starting point for the preparation of antitumor compounds, for example also for the formation of antibody conjugates.

[0024] When the amount of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester is 1 mol, preferably 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid C 1-4 In the second embodiment of the process according to the invention, the selected molar ratio can control the main process product (alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate, preferably C1-4-alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate, in particular ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate) in the range of >2.2 mol to, for example, 5 mol of chloromethylenedimethylimide chloride. is the ratio between ethyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate) and process by-products (alkyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate, preferably C1-4-alkyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate, in particular ethyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate). Although practically no by-products are obtained with the process according to the first embodiment of the invention, a mixture of main process product and process by-products can be obtained in a molar ratio in the range of >2.2 to, for example, 5. With increasing molar ratio, in addition to about 95 mol % of the main process product, the relative proportion of process by-products rises to about 5 mol %. In a second embodiment of the process according to the invention, it is not recommended to increase the molar ratio to > 5 mol of chloromethylenedimethylimine chloride per mole of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate.

[0025] Alkyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate obtainable as a process by-product of the process according to the invention carried out in its second embodiment can, for example, be subjected to a further process step in the form of ester hydrolysis to form 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid according to the procedure known from EP 2 468 716 A1, to which reference is explicitly made here.

[0026] It is also possible to carry out the method according to the second embodiment of the present invention and subject the process byproducts to ester hydrolysis together with the main process product. In other words, in this case, the product mixture consisting of the main process product and the process byproducts is not initially separated, but is subjected to ester hydrolysis together, based on the known procedures in EP 2468 716 A1, for example, explicitly cited herein. The resulting mixture of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid and 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid can then be separated using methods familiar to organic chemists, such as crystallization and / or preparative chromatography.

[0027] As mentioned above, the ester hydrolysis mentioned several times herein can be carried out according to the procedures known from EP 2 468 716 A1. For this purpose, the relevant isolated 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester, i.e. the corresponding formylated or non-formylated butyric acid alkyl ester, or an unisolated mixture of the two, is preferably mixed with an acid. The acid used is preferably an inorganic acid, in particular hydrochloric acid. The acid is usually used as a concentrated acid, for example as concentrated hydrochloric acid. The acid can be added to the mixture of formylated and non-formylated esters by mixing the acid with the ester (mixture) or with a solution thereof in a suitable organic solvent. The resulting mixture is then preferably stirred at a temperature in the range of 10°C to 80°C, more preferably at a temperature in the range of 15°C to 70°C, and even more preferably at a temperature in the range of 20°C to 60°C. The reaction time is preferably 30 minutes to six hours, more preferably one hour to four hours, and even more preferably one hour to three hours. After the reaction, any organic component contained in the mixture can be removed, such as a solvent or solvent residue. This can preferably be carried out by distilling these organic components. Then by conventional means, preferably by distillation, remove the acid contained in the mixture from the ester of hydrolysis. The substituted butyric acid in question is retained as residue, i.e. the butyric acid of the formylated replacement (4-[5-[bis (2-chloroethyl) amino]-4-formyl-1-methyl isophthalic acid H-benzo [d] imidazoles-2-yl] butyric acid) or the butyric acid of the non-formylated replacement (4-[5-[bis (2-chloroethyl) amino]-1-methyl isophthalic acid H-benzo [d] imidazoles-2-yl] butyric acid) or the related mixture of the formylated replacement butyric acid and the non-formylated replacement butyric acid.

[0028] 4-[5-[Bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid exhibits antitumor effects, for example, against the same types of cancer as 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid. This is demonstrated in the experiments shown in Example 3 below. 4-[5-[Bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid and its pharmaceutically acceptable salts, such as chloride, phosphate, sulfate, acetate, maleate, citrate or methanesulfonate, exhibit cancer cell killing or cancer cell growth inhibition effects even in the low IC50 concentration range of one hundred micromoles per liter, for example, against skin cancer, kidney cancer, lung cancer, brain tumors and pancreatic cancer. IC50 means "inhibitory concentration" at which 50% of cancer cells are killed.

[0029] The aldehyde group and the carboxyl group of 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid as reactive functional groups can provide starting points for a variety of intramolecular and intermolecular derivatization reactions and thus provide a starting point for the preparation of antitumor active compounds, for example also for the formation of antibody conjugates.

[0030] 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid, more precisely 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid in its function as an active ingredient, and its pharmaceutically acceptable salts can be used accordingly as listed below:

[0031] 1. In medicine, especially in human medicine, especially cancer medicine;

[0032] 2. In or for the therapeutic treatment of cancer (especially skin cancer, kidney cancer, lung cancer, brain tumor and pancreatic cancer);

[0033] 3. As a medicament, optionally in combination with other medicaments, in particular as a medicament in or for the therapeutic treatment of cancer, in particular skin cancer, kidney cancer, lung cancer, brain tumours and pancreatic cancer;

[0034] 4. As a medicinal product, in particular as a medicinal product for or in the therapeutic treatment of cancer (in particular skin cancer, kidney cancer, lung cancer, brain tumours and pancreatic cancer);

[0035] 5. In or for the manufacture of medicinal products, in particular medicinal products for the therapeutic treatment of cancer, in particular skin cancer, kidney cancer, lung cancer, brain tumours and pancreatic cancer.

[0036] Example 1 (Chloromethylenedimethylimine and 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzene and [d] imidazol-2-yl] butyric acid ethyl ester in a molar ratio of 2.0:1) :

[0037] 3.5g of chloromethylenedimethylimine chloride and 55.8g of dichloromethane were cooled to 5°C in a flask under stirring. 1°C cold solution of 5.0g of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid ethyl ester in 28.7g of dichloromethane was added in batches to the suspension, then heated to 40°C and stirred under reflux for 9 hours. Then cooled to 10°C and 10mL of water was added, pH was adjusted between 8 and 10 with 10% by weight potassium carbonate aqueous solution, stirred for 10 minutes and the two-phase system was transferred to a separatory funnel. The dichloromethane phase was separated. 46mL of dichloromethane was added to the aqueous phase, shaken out and the dichloromethane phase was separated. The combined dichloromethane phases were washed with 15mL of concentrated brine solution, and dichloromethane was removed under vacuum and by applying heat to a rotary evaporator. The residue was recrystallized from 10mL of ethyl acetate.

[0038] This gave 4.92 g of ethyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate (=89% yield, based on 5.0 g of ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate used).

[0039] Example 2 (Chloromethylenedimethylimine and 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-phenyl)imine and [d] imidazol-2-yl] butyric acid ethyl ester at a molar ratio of 4.0:1, followed by ester hydrolysis and product recovery) :

[0040] 7.0 g of chloromethylenedimethylimine chloride and 55.8 g of dichloromethane were cooled to 5 ° C in a flask under stirring. A 1 ° C cold solution of 5.0 g of ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate in 28.7 g of dichloromethane was added in batches to the suspension, then heated to 40 ° C and stirred under reflux for 9 hours. Then cooled to 10 ° C and 10 mL of water was added, the pH value was adjusted between 8 and 10 with 10 wt % aqueous potassium carbonate solution, stirred for 10 minutes and the two-phase system was transferred to a separatory funnel. The dichloromethane phase was separated. 46 mL of dichloromethane was added to the aqueous phase, and the dichloromethane phase was shaken out and separated. The combined dichloromethane phase was washed with 15 mL of concentrated brine. The washed dichloromethane phase was then mixed with 5.78g 32 wt % hydrochloric acid, and dichloromethane was removed under vacuum and by applying heat to a rotary evaporator. Another 23.8mL 32 wt % hydrochloric acid was added, and stirring was continued for 90 minutes at an internal temperature of 40°C. After cooling to 20°C, 0.58g activated carbon was added and stirred for 20 minutes, then the activated carbon was filtered off and rinsed with 24.8mL water. Then, at a bath temperature of 45°C and a vacuum of 15mbar, the solution was concentrated to 16.0g, a mixture of 19.75g water and 2.87g acetone was added, and cooled to 5°C within 60 minutes. The resulting suspension was stirred for 90 minutes at an internal temperature of 5°C, filtered and washed with 23mL cold water and 18mL ethyl acetate. After drying in vacuo, 3.58 g of 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid were obtained as the main product (=70% yield, based on 5.0 g of ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate used).

[0041] The acetone-based / water-based mother liquor obtained during filtration was freed of acetone under vacuum and the pH value was adjusted between 3 and 4 using 0.1 M NaOH. The resulting weakly acidic solution was purified by reverse phase chromatography (stationary phase: DuPont TM AmberChrom TM The precipitate was treated with 1% trifluoroacetic acid (TG) and 1% trifluoroacetic acid (TG) chromatographic resin (CG161M). A 0.1% trifluoroacetic acid aqueous solution with a gradient of acetonitrile increasing from 0% to 50% by weight was used as the eluent. The organic solvent in the eluent was removed in vacuo and then dried by lyophilization. Ethyl acetate was added to the lyophilized material thus recrystallized.

[0042] 0.25 g of 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid (=4.5% yield, based on 5.0 g of ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate used) was obtained as a by-product in the form of a yellow solid.

[0043] The yellow solid was analyzed by UV-VIS, HRMS, 1 H-NMR and 13 The product was identified as 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid by C-NMR spectroscopy.

[0044] UV-VIS in acetonitrile / water containing 0.1% HCOOH (nm): 249 (peak, broad), 295 (shoulder), 405 (peak, broad).

[0045] HRMS: C 17 H 21 O3N3Cl2, 386.10298 (Δm=-0.76ppm)

[0046] NMR data (in CDCl3) :

[0047] Position in a ring system or molecular fragment <![CDATA[ 1 H-NMR (ppm, intensity, multiplicity)]]> <![CDATA[ 13 C-NMR(ppm)]]> 2 -- 156.2 3a -- 130.3 4 -- 118.9 5 -- 151.7 6-CH 7.51, 1H, double peak 122.2 7-CH 7.93, 1H, double peak 118.7 7a -- 130.6 <![CDATA[NCH3]]> 4.03, 3H, single peak 31.3 <![CDATA[ CH2 CH2CH2COOH]]> 3.30, 2H, triplet 24.6 <![CDATA[CH2 CH2 CH2COOH]]> 2.11, 2H, multiple peaks 22.8 <![CDATA[CH2CH2 CH2 COOH]]> 2.49, 2H, triplet 32.8 COOH Width 174.1 <h2 style=";text-align:left;direction:ltr"><![CDATA[Cl(CH2 <h2 style=";text-align:left;direction:ltr"> CH2 <h2 style=";text-align:left;direction:ltr"> )2N]]><h2 style=";text-align:left;direction:ltr"> 3.70, 4H, triple peak 57.3 <h2 style=";text-align:left;direction:ltr"><![CDATA[Cl( <h2 style=";text-align:left;direction:ltr"> CH2 <h2 style=";text-align:left;direction:ltr"> CH2)2N]]><h2 style=";text-align:left;direction:ltr"> 3.60, 4H, triple peak 41.9 -CHO 10.7, 1H, singlet 190.2

[0048] Example 3

[0049] The selected cell lines were incubated with different concentrations of 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid (ranging from 1.5 μmol to 5 mmol per liter) at 37°C for 72 hours. The cells were then incubated with MTS solution (Promega) for 1 hour, and the effect of 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid on cell proliferation was determined colorimetrically at 490 nm. Cell growth was expressed as a percentage of the corresponding control (0.5 wt % dimethyl sulfoxide in water). The corresponding IC50 values ​​were calculated based on the data.

[0050] organ Cell lines IC50(mol / L) skin A375 <![CDATA[1.3·10 -3 <!-- 6 -->]]> kidney Caki-1 <![CDATA[1.6·10 -3 ]]> lung Calu-6 <![CDATA[1.3·10 -3 ]]> brain U87MG <![CDATA[2.9·10 -3 ]]> pancreas BxPC-3 <![CDATA[7.4·10 -4 ]]>

Claims

1. A process for preparing alkyl 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate, wherein alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate is reacted with chloromethylenedimethylimide chloride.

2. The method according to claim 1, wherein the 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid alkyl ester is selected from C 1-4 Alkyl esters.

3. The method according to claim 1 or 2, wherein ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate is used.

4. The process according to any one of the preceding claims, wherein a molar ratio of chloromethylenedimethylimine chloride in the range of 2.0 mol to 2.2 mol per mole of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate is used.

5. The process according to claim 1, wherein a molar ratio of chloromethylenedimethylimine chloride in the range of >2.2 mol to 5 mol per mole of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyrate is used.

6. Alkyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate obtainable as a by-product of the process according to claim 5.

7. The method according to claim 2, wherein the amount of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid C used is 1. 1-4 The molar ratio of alkyl ester to chloromethylenedimethyliminochloride ranges from >2.2 mol to 5 mol.

8. 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid C obtainable as a by-product of the process according to claim 7 1-4 Alkyl esters.

9. The process according to claim 3, wherein a molar ratio of chloromethylenedimethylimine chloride in the range of >2.2 mol to 5 mol per mole of ethyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate is used.

10. Ethyl 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoate obtainable as a by-product of the process according to claim 9.

11. The process according to any one of claims 5, 7 or 9, wherein the process by-product thus obtained is subjected to subsequent ester hydrolysis to form 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid.

12. The process according to claim 11, wherein the process by-products are subjected to ester hydrolysis together with the main process products.

13. 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid obtainable as a product of the process according to claim 11 or 12.

14. 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butanoic acid or a pharmaceutically acceptable salt thereof for use in medicine.